vxm01
Biologicalexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01486329)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vascular endothelial growth factor receptor 2Immunity, active
KDR immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vxm01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03750071 | Phase 1/Phase 2 (Phase 2) | Nov 21, 2018 | Heidelberg Clinical Research Centre, Merck KGaA, Pfizer, Vaximm GmbH |
| NCT02718443 | Phase 1 | May 1, 2016 | Vaximm GmbH |
| NCT02718430 | Phase 1 | Feb 1, 2016 | University of Heidelberg, Vaximm GmbH |
| NCT01486329 | Phase 1 | Dec 1, 2011 | University of Heidelberg, Vaximm GmbH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaximm GmbH | For profit | 4 | 4 | 2 | 2011 |
| University of Heidelberg | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Heidelberg Clinical Research Centre | For profit | 1 | 0 | 1 | 2018 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2018 |
| Pfizer | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1